IDEAYA Biosciences, Inc. Common Stock (IDYA) Stock Price

IDYAStock

$32.85+18.63%52W

Market Cap$3.17B

P/E—

PEG Ratio—

Div yield—

Beta0.06

IDYA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-8.36%

Price vs S&P 500 (4W)-14.14%

VGM Score63.68

Book Value / Share (Quarterly)$12.44

P/TBV (Annual)5.83x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)62.54%

Cash Flow / Share (Quarterly)$-1.18

Price vs S&P 500 (YTD)-16.90%

Net Profit Margin (TTM)-74.75%

EPS (TTM)$-1.94

10-Day Avg Trading Volume0.78M

EPS Excl Extra (TTM)$-1.94

Revenue Growth (5Y)62.10%

EPS (Annual)$-1.28

ROI (Annual)-11.11%

Net Profit Margin (5Y Avg)-949.88%

Cash / Share (Quarterly)$8.60

Revenue Growth QoQ (YoY)55.37%

ROA (Last FY)-10.25%

Revenue Growth TTM (YoY)3118.14%

EBITD / Share (TTM)$-2.39

ROE (5Y Avg)-17.70%

Operating Margin (TTM)-92.66%

Cash Flow / Share (Annual)$-0.84

P/B Ratio2.64x

P/B Ratio (Quarterly)2.96x

Net Income / Employee (Annual)$-784,100

EV / Revenue (TTM)12.37x

ROA (TTM)-15.11%

EPS Incl Extra (Annual)$-1.28

Current Ratio (Annual)11.34x

Quick Ratio (Quarterly)10.21x

3-Month Avg Trading Volume0.95M

52-Week Price Return18.63%

Revenue / Employee (TTM)$1,614,700

Tangible BV / Share (Quarterly)$8.67

P/S Ratio (Annual)14.49x

Asset Turnover (Annual)0.20x

52-Week High$42.68

Operating Margin (5Y Avg)-1124.28%

EPS Excl Extra (Annual)$-1.28

CapEx CAGR (5Y)37.04%

Tangible BV CAGR (5Y)102.18%

26-Week Price Return1.55%

Quick Ratio (Annual)10.97x

13-Week Price Return-8.78%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.45x

Enterprise Value$2.90B

Revenue / Share Growth (5Y)25.61%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)11.63%

Revenue / Employee (Annual)$1,508,300

Pretax Margin (Annual)-51.99%

Cash / Share (Annual)$7.28

3-Month Return Std Dev34.20%

Net Income / Employee (TTM)$-1,207,000

ROE (Last FY)-11.11%

EPS Basic Excl Extra (Annual)$-1.28

Receivables Turnover (TTM)73.20x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.94

Receivables Turnover (Annual)73.20x

ROI (TTM)-16.47%

P/S Ratio (TTM)13.54x

Pretax Margin (5Y Avg)-949.88%

Revenue / Share (Annual)$2.47

Tangible BV / Share (Annual)$7.25

Price vs S&P 500 (52W)3.10%

Year-to-Date Return-4.98%

5-Day Price Return-8.90%

EPS Normalized (Annual)$-1.28

ROA (5Y Avg)-16.05%

Net Profit Margin (Annual)-51.99%

Month-to-Date Return-14.50%

Cash Flow / Share (TTM)$-1.89

EBITD / Share (Annual)$-1.77

Operating Margin (Annual)-72.84%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-17.70%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.94

P/TBV (Quarterly)4.01x

P/B Ratio (Annual)2.96x

Pretax Margin (TTM)-74.75%

Book Value / Share (Annual)$11.65

Price vs S&P 500 (13W)-11.46%

Beta0.06x

P/FCF (Annual)57.66x

Revenue / Share (TTM)$2.54

ROE (TTM)-16.47%

52-Week Low$26.81

vGradeD

gGradeA

mGradeB

vgmGradeB

IDYA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$1.05	-$1.22	-16.17%(-$0.17)
Q1 2026	May 5, 2026	-$0.98	-$1.11	-13.46%(-$0.13)
Q4 2025	Feb 17, 2026	-$0.95	-$0.94	+0.63%(+$0.01)
Q3 2025	Nov 4, 2025	-$0.55	$1.33	+341.84%(+$1.88)
Q2 2025	Aug 5, 2025	-$0.79	-$0.88	-10.79%(-$0.09)

IDYA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.24

4.17

4.23

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IDYAIDEAYA Biosciences, Inc. Common Stock	D	A	B	13.5x	3118.1%	—	—	$32.85
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About IDEAYA Biosciences, Inc. Common Stock

IDEAYA Biosciences is an oncology-focused precision medicine company developing targeted cancer therapies selected using molecular diagnostics and biomarker validation. It combines small molecule drug discovery with translational research to identify patient populations most likely to benefit from its treatments. The company has six clinical-stage candidates and multiple earlier-stage preclinical programs in development.

IDYA Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$1.17

Revenue estimate$6.98M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

IDYA Insider Transactions

SellOct 6, 2026
HATA YUJIRO S.
Chief Executive Officer
Shares: 26,338Value: $985,397

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

AVNTAvient CorporationPlastics & Resins
RLAYRelay Therapeutics, Inc. Common StockBiological Products
TARSTarsus Pharmaceuticals, Inc. Common StockBiological Products
SMGThe Scotts Miracle-Gro CompanyAgricultural Chemicals
COTYCOTY INCCosmetics & Toiletries
DNLIDenali Therapeutics Inc. Common StockBiological Products
FULH.B. Fuller CompanyAdhesives & Sealants
WDFCWd-40 CoIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$26.81

High$42.68